In this study, we demonstrated that ICA1 alters APP processing and shifts it to non‐amyloid pathways by regulating the PICK1‐PKCα signaling pathway, and we suggested ICA1 as a potential therapeutic target for AD therapy by modulating APP processing. Here, PRKCA is linked to Alzheimer disease.